Artal Group S.A. Alnylam Pharmaceuticals, Inc. Transaction History

Artal Group S.A.

$214 Million
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $173,169 - $198,478	936 New	936 $178,000
Q2 2022 Aug 11, 2022	SELL	$120.42 - $169.29 $6.02 Million - $8.46 Million	-50,000 Reduced 7.69%	600,000 $87.5 Million
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $7.98 Million - $10.5 Million	-50,000 Reduced 7.14%	650,000 $110 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $8.49 Million - $10.4 Million	-50,000 Reduced 6.67%	700,000 $132 Million
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $6.34 Million - $8.78 Million	-50,000 Reduced 6.25%	750,000 $106 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $12.1 Million - $16.5 Million	-100,000 Reduced 11.11%	800,000 $116 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $20.8 Million - $31.3 Million	-200,000 Reduced 18.18%	900,000 $133 Million
Q1 2020 May 14, 2020	BUY	$93.12 - $133.99 $9.31 Million - $13.4 Million	100,000 Added 10.0%	1,100,000 $120 Million
Q4 2019 Feb 13, 2020	BUY	$74.51 - $124.23 $22.4 Million - $37.3 Million	300,000 Added 42.86%	1,000,000 $115 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $21.3 Million - $26.3 Million	300,000 Added 75.0%	700,000 $56.3 Million
Q2 2019 Aug 09, 2019	SELL	$65.86 - $92.79 $3.29 Million - $4.64 Million	-50,000 Reduced 11.11%	400,000 $29 Million
Q1 2019 May 10, 2019	SELL	$72.76 - $93.45 $3.64 Million - $4.67 Million	-50,000 Reduced 10.0%	450,000 $42.1 Million
Q4 2018 Feb 11, 2019	SELL	$62.67 - $88.33 $6.27 Million - $8.83 Million	-100,000 Reduced 16.67%	500,000 $36.5 Million
Q3 2018 Nov 09, 2018	SELL	$87.52 - $122.67 $4.38 Million - $6.13 Million	-50,000 Reduced 7.69%	600,000 $52.5 Million
Q2 2018 Aug 10, 2018	BUY	$88.31 - $107.8 $4.42 Million - $5.39 Million	50,000 Added 8.33%	650,000 $64 Million
Q1 2018 May 10, 2018	BUY	$115.92 - $148.54 $17.4 Million - $22.3 Million	150,000 Added 33.33%	600,000 $71.5 Million
Q4 2017 Feb 09, 2018	BUY	$114.49 - $139.98 $22.9 Million - $28 Million	200,000 Added 80.0%	450,000 $57.2 Million
Q3 2017 Nov 08, 2017	BUY	$72.53 - $118.27 $18.1 Million - $29.6 Million	250,000	250,000 $29.4 Million

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$3.87 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$2.96 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.24 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.23 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.16 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account